These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P; Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293 [TBL] [Abstract][Full Text] [Related]
3. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment. Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959 [TBL] [Abstract][Full Text] [Related]
4. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor. Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197 [TBL] [Abstract][Full Text] [Related]
5. MC4R Variants Modulate α-MSH and Setmelanotide Induced Cellular Signaling at Multiple Levels. Rodríguez Rondón AV; Welling MS; van den Akker ELT; van Rossum EFC; Boon EMJ; van Haelst MM; Delhanty PJD; Visser JA J Clin Endocrinol Metab; 2024 Sep; 109(10):2452-2466. PubMed ID: 38567654 [TBL] [Abstract][Full Text] [Related]
6. Differential control of metabolic and cardiovascular functions by melanocortin-4 receptors in proopiomelanocortin neurons. do Carmo JM; da Silva AA; Rushing JS; Pace B; Hall JE Am J Physiol Regul Integr Comp Physiol; 2013 Aug; 305(4):R359-68. PubMed ID: 23842677 [TBL] [Abstract][Full Text] [Related]
7. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach. Falls BA; Zhang Y ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591 [TBL] [Abstract][Full Text] [Related]
16. Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome. Lazareva J; Sisley SR; Brady SM; Smith ACM; Elsea SH; Pomeroy JJ; Roth CL; Sprague JE; Wabitsch M; Garrison J; Yanovski JA Obes Res Clin Pract; 2024; 18(4):301-307. PubMed ID: 38987029 [TBL] [Abstract][Full Text] [Related]
17. The melanocortin pathway and control of appetite-progress and therapeutic implications. Baldini G; Phelan KD J Endocrinol; 2019 Apr; 241(1):R1-R33. PubMed ID: 30812013 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome. Lazareva J; Brady SM; Yanovski JA Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719 [TBL] [Abstract][Full Text] [Related]
19. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. De Jonghe BC; Hayes MR; Zimmer DJ; Kanoski SE; Grill HJ; Bence KK Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E644-51. PubMed ID: 22761160 [TBL] [Abstract][Full Text] [Related]
20. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Kumar KG; Sutton GM; Dong JZ; Roubert P; Plas P; Halem HA; Culler MD; Yang H; Dixit VD; Butler AA Peptides; 2009 Oct; 30(10):1892-900. PubMed ID: 19646498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]